SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Butorphanol Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Butorphanol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Walton Manor, Walton
   MK7 7AJ Milton Keynes - United Kingdom
   Telephone : 908-740-4000
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Specific target organ toxicity - single exposure, Category 2
   H371: May cause damage to organs.

   Specific target organ toxicity - repeated exposure, Category 2
   H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :

   Signal word : Warning

   Hazard statements :
   H371 May cause damage to organs.
   H373 May cause damage to organs through prolonged or repeated exposure.

   Precautionary statements : Prevention:
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Butorphanol Formulation

Version 2.3 Revision Date: 23.03.2020 SDS Number: 918975-00009 Date of last issue: 13.09.2019
Date of first issue: 03.10.2016

P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P308 + P311 IF exposed or concerned: Call a POISON CENTER/doctor.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate

2.3 Other hazards
None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate</td>
<td>58786-99-5</td>
<td>261-443-5</td>
<td></td>
<td>Acute Tox. 4; H302 Repr. 2; H361fd STOT SE 1; H370 STOT RE 1; H372 Aquatic Chronic 3; H412</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.
Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Avoid inhalation of vapour or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working
place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-(Cyclobutylmethyl)morphinan-3,14-diyl [S- (R*,R*)]-2,3-dihydroxysuccinate</td>
<td>58786-99-5</td>
<td>TWA</td>
<td>3 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>30 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

- **Material**: Chemical-resistant gloves
- **Remarks**: Consider double gloving.

**Skin and body protection**

- **Work uniform or laboratory coat.** Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**

- **If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.** Equipment should conform to BS EN 143
- **Filter type**: Particulates type (P)

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

- **Appearance**: liquid
- **Colour**: colourless
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: 100 °C
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Relative density**: No data available
- **Density**: No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Butorphanol Formulation

Solubility(ies)
  Water solubility: No data available
  Partition coefficient: n-octanol/water: Not applicable
  Auto-ignition temperature: No data available
  Decomposition temperature: No data available

Viscosity
  Viscosity, kinematic: No data available

Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
  Flammability (liquids): No data available
  Particle size: Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
  Not classified as a reactivity hazard.

10.2 Chemical stability
  Stable under normal conditions.

10.3 Possibility of hazardous reactions
  Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
  Conditions to avoid: None known.

10.5 Incompatible materials
  Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
  No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
  Information on likely routes of exposure:
    Inhalation
    Skin contact
    Ingestion
    Eye contact
## Acute toxicity

Not classified based on available information.

### Product:

<table>
<thead>
<tr>
<th>Method</th>
<th>Acute toxicity estimate: &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Method: Calculation method</td>
</tr>
</tbody>
</table>

### Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:

<table>
<thead>
<tr>
<th>Method</th>
<th>Acute oral toxicity: LD50 (Mouse): 395 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LD50 (Dog): &gt; 50 mg/kg</td>
</tr>
<tr>
<td></td>
<td>LD50 (Monkey): &gt; 50 mg/kg</td>
</tr>
<tr>
<td>Acute inhalation toxicity</td>
<td>Remarks: No data available</td>
</tr>
<tr>
<td>Acute dermal toxicity</td>
<td>Remarks: No data available</td>
</tr>
</tbody>
</table>

### Skin corrosion/irritation

Not classified based on available information.

### Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:

<table>
<thead>
<tr>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

### Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Assessment</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermal</td>
<td>Does not cause skin sensitisation.</td>
<td>negative</td>
</tr>
</tbody>
</table>
Germ cell mutagenicity
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Result: negative

Carcinogenicity
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Reproductive toxicity
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Oral
  - Fertility: LOAEL: 160 mg/kg body weight
  - Result: Effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Subcutaneous
  - Developmental Toxicity: LOAEL: 1 mg/kg body weight
  - Result: No teratogenic effects, Increased stillbirths

  Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 30 mg/kg body weight
  - Result: No teratogenic effects, Maternal toxicity observed., Postimplantation loss.
Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0.5 mg/kg body weight  
Result: Maternal toxicity observed.

Reproductive toxicity - Assessement  
: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure  
May cause damage to organs.

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:  
Target Organs: Central nervous system  
Assessment: Causes damage to organs.

STOT - repeated exposure  
May cause damage to organs through prolonged or repeated exposure.

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:  
Target Organs: Blood, Central nervous system  
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:  
Species: Rat  
LOAEL: 0.4 mg/kg  
Application Route: Subcutaneous  
Exposure time: 6 Months  
Target Organs: Blood, Central nervous system

Species: Monkey  
LOAEL: 0.15 mg/kg  
Application Route: Intramuscular  
Exposure time: 6 Months  
Target Organs: Central nervous system

Species: Dog  
LOAEL: 0.1 mg/kg  
Application Route: Intramuscular  
Exposure time: 3 Months  
Symptoms: reduced body weight gain
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diy1 [S-(R*,R*)]-2,3-dihydroxysuccinate:
Ingestion: Symptoms: Drowsiness, Sweating, Nausea, Dizziness, Vertigo, Palpitation, respiratory depression

SECTION 12: Ecological information

12.1 Toxicity

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 38.1 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Butorphanol Formulation

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined
15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

OTHER INFORMATION

A Chemical Safety Assessment has not been carried out.

OTHER INFORMATION

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

FULL TEXT OF H-STATEMENTS

H302 : Harmful if swallowed.
H361fd : Suspected of damaging fertility. Suspected of damaging the unborn child.
H370 : Causes damage to organs if swallowed.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H412 : Harmful to aquatic life with long lasting effects.

FULL TEXT OF OTHER ABBREVIATIONS

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICPO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature;
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Butorphanol Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3</td>
<td>23.03.2020</td>
<td>918975-00009</td>
<td>13.09.2019</td>
<td>03.10.2016</td>
</tr>
</tbody>
</table>

SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:
- STOT SE 2 (H371)
- STOT RE 2 (H373)

Classification procedure:
- Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

GB / EN